On June 30th, 2023, 908 DEVICES ($NASDAQ:MASS) reported their earnings results for the second quarter of their fiscal year 2023, revealing a total revenue of USD 12.1 million, an 8.8% increase from the previous year. Net income for this quarter amounted to USD -9.4 million, an improvement from last year’s -8.1 million.
GoodWhale has conducted an analysis of 908 DEVICES‘ wellbeing, with a Risk Rating score of medium. This indicates that, in terms of financial and business aspects, 908 DEVICES is moderately risky for investors. GoodWhale has found one risk warning in the company’s balance sheet, which can be accessed by registering with GoodWhale. In general, 908 DEVICES appears to be a viable investment option. However, potential investors are advised to conduct further research into the company’s financial and business health before committing to any investments. GoodWhale provides the necessary tools and resources to evaluate the riskiness of any potential investment. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for 908 Devices. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for 908 Devices. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for 908 Devices. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for 908 Devices are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
The company’s products are used in a variety of industries, including healthcare, pharmaceuticals, food and beverage, environmental testing, and forensics. 908 Devices Inc’s main competitors are Cell Kinetics Ltd, Belluscura PLC, and Armm Inc.
Lumicell Inc is a medical device company that develops and commercializes proprietary technologies for the treatment of cancer. The company’s products are based on its proprietary Selective Photothermolysis System, which enables the delivery of energy selectively to cancer cells while sparing healthy tissue. Lumicell’s products are designed to improve patient outcomes and reduce treatment costs.
– Belluscura PLC ($LSE:BELL)
Belluscura PLC is a medical technology company that develops, manufactures, and markets medical devices for the treatment of respiratory disorders and other conditions. The company has a market cap of 77.01M as of 2022 and a Return on Equity of -18.87%. Belluscura PLC is headquartered in London, United Kingdom.
Investors in 908 DEVICES were pleased with the company’s performance in the second quarter of FY2023, as total revenue increased 8.8% year-over-year to USD 12.1 million. Despite a net loss of USD -9.4 million, the loss narrowed compared to the prior year’s -8.1 million. Stock prices responded positively to the earnings report, indicating investor confidence in the company’s future outlook. With an attractive growth rate and strong financials, 908 DEVICES remains a solid investment for long-term investors.